Filing summary
Entity and period: The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2016, filed November 4, 2016. This does not match the request metadata naming Crescent BioPharma, Inc.; verify the issuer before relying on this summary.
Business context
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates and has no approved products or product-sales revenue. Its programs include GMI-1271 for acute myeloid leukemia (AML) and multiple myeloma (MM), GMI-1359, and rivipansel, which Pfizer licenses and develops.
Financial performance and position
| Metric | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
|---|---|---|
| Revenue | $18,500 | $18,500 |
| Research and development expense | $5.92 million | $17.22 million |
| General and administrative expense | $1.98 million | $6.35 million |
| Net loss | $7.85 million | $23.48 million |
| Basic and diluted loss per share | $0.34 | $1.14 |
- Cash and cash equivalents were $45.28 million at September 30, 2016, versus $46.80 million at December 31, 2015. Total assets were $48.01 million; total liabilities were $6.26 million; stockholders’ equity was $41.75 million.
- Nine-month operating cash use was $23.78 million, investing cash use was $0.27 million, and financing cash inflow was $22.52 million. Cash declined by $1.52 million over the period.
- No conventional debt balance is presented in the supplied filing. Reported contractual obligations consisted primarily of operating-lease payments totaling $7.16 million through the lease term ending October 2023. The company also reported a one-time option to terminate the lease effective October 2020.
- Profit margins are not meaningful for this pre-commercial company with negligible revenue and ongoing development costs.
Changes versus comparable periods
- Third-quarter revenue was $18,500 versus none in 2015; quarterly net loss widened to $7.85 million from $7.17 million. R&D rose 18%, mainly reflecting clinical trials for GMI-1271 and GMI-1359; G&A fell 7%, primarily on lower legal and professional costs.
- Nine-month revenue fell to $18,500 from $20.04 million, which included a $20 million Pfizer milestone in 2015. Nine-month net loss increased to $23.48 million from $3.89 million, largely reflecting the absence of that milestone revenue.
- Nine-month R&D declined 5% to $17.22 million, chiefly because the 2015 period included a $2 million University of Basel milestone-related expense that did not recur. G&A increased 9% to $6.35 million, primarily due to personnel and stock-based compensation.
Outlook, risks and other notable items
- Management estimated that cash and cash equivalents at quarter-end would fund operating expenses and capital needs through the second quarter of 2018. This is an estimate based on assumptions; spending or trial timing could reduce the runway.
- Management expected R&D spending to increase as clinical programs advance. The filing describes the Phase 2 portion of the GMI-1271 AML trial as underway, a Phase 1 GMI-1271 MM trial initiated in September 2016, and a Phase 1 GMI-1359 healthy-volunteer trial initiated in August 2016.
- Pfizer may owe substantial future development, regulatory and sales milestones, plus royalties, under the rivipansel agreement; timing and achievement are uncertain. The company owes the University of Basel 10% of qualifying future Pfizer milestone and royalty receipts.
- The company warned that it may need additional financing and that capital may not be available on acceptable terms or at all; future equity financing could dilute shareholders. It may have to delay or reduce development if it cannot raise funds.
- The filing reported no material legal proceedings, no material change to previously disclosed risk factors, effective disclosure controls, and no off-balance-sheet arrangements. It stated that market risk was primarily interest-rate exposure and that an immediate 100-basis-point change would not materially affect cash-equivalent fair value.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for GlycoMimetics, Inc., not Crescent BioPharma, Inc.
- Check subsequent clinical-trial results, enrollment, regulatory progress and development spending for GMI-1271 and GMI-1359.
- Assess the assumptions behind the stated cash runway and the company’s need and ability to obtain additional financing.
- Verify the status and terms of potential Pfizer milestones and royalties, including the related University of Basel payment obligation.
- Review the full filing and subsequent disclosures for lease commitments, share issuance and dilution, and any developments after September 30, 2016.